Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of Oncology Institute Inc (NASDAQ: TOI) was $3.23 for the day, down -0.62% from the previous closing price of $3.25. In other words, the price has decreased by -$0.62 from its previous closing price. On the day, 0.95 million shares were traded. TOI stock price reached its highest trading level at $3.3699 during the session, while it also had its lowest trading level at $3.21.
Ratios:
Our analysis of TOI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.37 and its Current Ratio is at 1.62.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Noble Capital Markets on July 23, 2025, initiated with a Outperform rating and assigned the stock a target price of $8.
On July 16, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $6.
On May 15, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $7.BTIG Research initiated its Buy rating on May 15, 2025, with a $7 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 19 ’25 when Hively Brad sold 20,221 shares for $4.06 per share. The transaction valued at 82,097 led to the insider holds 622,980 shares of the business.
M33 Growth I L.P. sold 673,676 shares of TOI for $2,054,712 on Jun 05 ’25. The Director now owns 13,950,557 shares after completing the transaction at $3.05 per share. On Jun 05 ’25, another insider, M33 Growth I L.P., who serves as the Director of the company, sold 76,324 shares for $3.05 each. As a result, the insider received 232,788 and left with 1,272,724 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TOI now has a Market Capitalization of 302020512 and an Enterprise Value of 375279392. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.71. Its current Enterprise Value per Revenue stands at 0.884 whereas that against EBITDA is -9.374.
Stock Price History:
The Beta on a monthly basis for TOI is 0.13, which has changed by 9.590164 over the last 52 weeks, in comparison to a change of 0.1716845 over the same period for the S&P500. Over the past 52 weeks, TOI has reached a high of $4.50, while it has fallen to a 52-week low of $0.13. The 50-Day Moving Average of the stock is -3.81%, while the 200-Day Moving Average is calculated to be 76.90%.
Shares Statistics:
TOI traded an average of 2.06M shares per day over the past three months and 1345980 shares per day over the past ten days. A total of 93.28M shares are outstanding, with a floating share count of 46.20M. Insiders hold about 50.60% of the company’s shares, while institutions hold 27.86% stake in the company. Shares short for TOI as of 1755216000 were 6248161 with a Short Ratio of 3.04, compared to 1752537600 on 7145146. Therefore, it implies a Short% of Shares Outstanding of 6248161 and a Short% of Float of 8.1499994.
Earnings Estimates
Its stock is currently analyzed by 3 different market analysts. The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.06 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.49 and -$0.6 for the fiscal current year, implying an average EPS of -$0.55. EPS for the following year is -$0.21, with 2.0 analysts recommending between -$0.14 and -$0.28.
Revenue Estimates
For the next quarter, 3 analysts are estimating revenue of $126.77M. There is a high estimate of $128.1M for the next quarter, whereas the lowest estimate is $124.5M.
Based on 3 analysts’ estimates, the company’s revenue will be $564.43M in the next fiscal year. The high estimate is $582.4M and the low estimate is $550M.
